Omniab, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Omniab, Inc. (Nasdaq: OABI) on July 13, 2026. The report discloses the appointment of a new Chief Operating Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes and Executive Appointment
Effective July 13, 2026, Amechi Nwachuku was appointed as Chief Operating Officer. Mr. Nwachuku brings over two decades of experience in life sciences, with recent roles at Thermo Fisher Scientific, SCIEX (Danaher), Beckman Coulter Diagnostics (Danaher), Johnson & Johnson, and Bayer.
Compensatory Arrangements and Outlook
- Base Salary: $445,000 annually.
- Target Bonus: 45% of annual base salary (prorated for 2026).
- Signing Bonus: $20,000.
- Equity Grant: 800,000 stock options granted effective August 1, 2026, vesting over four years (12.5% at six months, then monthly).
- Severance (Standard): Upon involuntary termination without cause, Mr. Nwachuku is eligible for base salary for a period of two months plus one week per year of service, plus continued health coverage.
- Severance (Change in Control): If terminated without cause or resigns for good reason within 24 months of a change in control, benefits include one times base salary, one times the greater of the current or prior year's target bonus, and 12 months of health premiums. All time-based equity awards would vest immediately.
Investor Verification Checklist
- Verify the closing stock price on August 1, 2026, to determine the exercise price of the 800,000 options granted.
- Review the Company's 2022 Incentive Award Plan to confirm the total pool of shares available for future grants.
- Assess the impact of the new COO's commercial background on the Company's strategic direction in life sciences tools and diagnostics.
- Monitor future filings for any changes to the Company's capital structure resulting from the vesting of these options.